Introduction {#Sec1}
============

The "gold standard" reference for determining hepatic histology in chronic hepatitis B (CHB) used to be liver biopsy. Because of the limitations of liver biopsy, however, several noninvasive biomarkers have been validated since 2001.

Between 2001 and 2008, two techniques---a serum biomarker (FibroTest; Biopredictive, Paris, France; FibroSure; LabCorp, Burlington, USA) and liver stiffness measurement (LSM) (Fibroscan; Echosens, Paris, France)---were extensively validated using biopsy, and six other biomarkers also were investigated but with fewer studies: Enhanced Liver Fibrosis (ELF) test, Fibrometer, Fibrospect, FIB-4 (age, platelets, aspartate aminotransferase \[AST\] and alanine aminotransferase \[ALT\]), Hepascore, and APRI (AST-to-platelet ratio index) \[[@CR1]\]. According to meta-analyses, most of these studies were initially published in patients with chronic hepatitis C (CHC). In eight previous meta-analyses published between 2002 and 2008 \[[@CR2]--[@CR9]\], only FibroTest had been validated in five studies including only patients with CHB \[[@CR10]--[@CR13], [@CR14]•\]. No meta-analysis was possible for other biomarkers.

Unlike CHC \[[@CR7]\], no guidelines recommend biomarkers for routine clinical use in patients with CHB, although "they might be helpful on a case-by-case basis" \[[@CR15]••\].

The primary objective of this review is to update the last published meta-analyses on the clinical validation of serum biomarkers and LSM in the management of patients with CHB. We used an integrated database of individual data and the new recommended Obuchowski measures to prevent spectrum effect and multiple testing \[[@CR16]••\], and we searched for prognostic studies.

Methods {#Sec2}
=======

This study was conducted according to the principles expressed in the Declaration of Helsinki. Two meta-analyses were performed: one combined all identified published studies, and the other used an integrated database combining individual data provided by authors.

Design of Meta-Analysis of Published Studies {#Sec3}
--------------------------------------------

The primary outcome was the differentiation of nonadvanced fibrosis from advanced fibrosis, defined using the METAVIR scoring system (F0--F1 vs F2--F4) \[[@CR17]\]. We chose this endpoint because it seems at least as rational as the viral load to assess the severity of CHB \[[@CR15]••, [@CR18]••\]. The other endpoints were the performance for the diagnosis of cirrhosis and the prognostic values.

To select published studies, we used the Standards for Reporting of Diagnostic Accuracy (STARD) criteria and the Cochrane Database of Systematic Reviews (CDSR) methods \[[@CR19]\]. Key STARD criteria include factors such as whether (1) the study population was relevant to the clinical question being addressed; (2) there was a careful description of the population from which the patients were drawn, as well as actual inclusions and exclusions; (3) recruitment and the mode of sampling were carefully described; (4) researchers interpreting the noninvasive test were blinded to the reference test result; and (5) sufficient data were provided to complete a 2 × 2 table of true and false positive and negative diagnoses. Studies published only with an abstract provided insufficient data and were excluded.

### Search Strategy {#Sec4}

We searched MEDLINE with the keywords "HBV, Fibrosis, FibroTest, Fibroscan, Elastography, ELF, Fibrospect, and Hepascore." We hand-searched key journals (*Gastroenterology, Hepatology, Journal of Hepatology, Gut, Journal of Viral Hepatitis*, and *American Journal of Gastroenterology*) from February 2001 to December 2010 to validate the search, as well as the references of publications identified by previous searches.

### Inclusion and Exclusion Criteria {#Sec5}

We excluded all studies except those that included patients with CHB; stated that all patients had had the biomarker and liver biopsy; provided data for true positives and negatives, false positives and negatives, and area under the receiver operating curves (AUROCs) for advanced fibrosis; stated that the biomarker had been assessed blind to the biopsy; and stated the method used for defining the degree of fibrosis. We were careful to avoid including data from duplicate publications. We excluded the following biomarkers, which combined ALT or AST in their formula with a risk of confounding impact of necro-inflammatory histologic activity on the fibrosis stage estimates: Fibrometer, FIB-4, and APRI \[[@CR20]--[@CR22]\].

### Statistical Methods Used in AUROCs Meta-Analysis {#Sec6}

Meta-analysis was performed twice, once according to the absolute value of the not-standardized AUROCs (AUROC) and once according to the AUROCs standardized for the spectrum of fibrosis stages (StAUROC). We previously demonstrated that the AUROCs were highly related to the Difference between Advanced and Non Advanced mean fibrosis stages (DANA); the StAUROC is the AUROC adjusted for the difference of the observed DANA versus a standard DANA of 2.5 fibrosis METAVIR units (DANA = 2.5, if there was a uniform prevalence of 0.20 in each of the five stages). The regression between the AUROCs and the whole DANA spectrum of published studies in CHB enables the AUROC to be estimated from the DANA. The regression formula for standardizing AUROCs estimated from different stage prevalences, according to previously published method and to the identified biomarkers, was: $\documentclass[12pt]{minimal}
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                \begin{document}$$ {\hbox{StAUROC}} = {\hbox{AUROC}} + 0.0{482} \times \left( {{2}.{5}\,{\hbox{DANA}}} \right) $$\end{document}$ \[[@CR20], [@CR23]••\].

The AUROC was estimated by the empirical (nonparametric) method of Delong et al. \[[@CR24]\], equivalent to the Mann--Whitney statistic, and compared using the paired method of Zhou et al. \[[@CR25]\]. The meta-analysis was stratified according to the biomarkers. The analysis used a random effect model, and the heterogeneity between effects according to publications and biomarkers was tested using Cochran's Q heterogeneity test. A sensitivity analysis was also performed according to the independence of authors for FibroTest.

Design of Individual Data Meta-Analysis {#Sec7}
---------------------------------------

### Patients {#Sec8}

Patients with individual data included in the database were described in a previous overview of FibroTest in patients with chronic liver diseases \[[@CR8]\]. For the present study, only patients with hepatitis B virus (HBV) were included. Patients' data were included with the agreement of authors in the present study if they met the following optimal conditions of analyses: they must have been included in a validation study including FibroTest, ALT, and biopsy with METAVIR scoring system for fibrosis score, according to preanalytical and analytical recommendations. All patients have CHB with positive polymerase chain reaction test. All biomarkers have been assessed blinded to clinical, biochemical, or histologic patient characteristics.

### Biochemical Analysis {#Sec9}

The dosage methods for each of the FibroTest parameters followed the standardized conditions, as listed in the technical recommendations (<http://www.biopredictive.com>).

### Liver Biopsies {#Sec10}

Liver biopsies were processed using standard techniques. A pathologist who was unaware of the biomarkers evaluated the fibrosis stage according to the METAVIR scoring system \[[@CR17]\]. Fibrosis was staged on a scale of 0 to 4: F0---no fibrosis; F1---portal fibrosis without septa; F2---few septa; F3---numerous septa without cirrhosis; and F4---cirrhosis. Biopsies were performed with a 16-gauge Hepafix Luer-Lock needle (Braun Melsungen, Melsungen, Germany) in the Paris center, and with various needles in the multicenter study from Marseille.

### Statistical Analysis of Integrated Database {#Sec11}

The use of the AUROC raises two methodologic issues. First, its use is based on the assumption that the gold standard is binary, whereas fibrosis staging uses an ordinal scale. This difference implies that fibrosis stages in the study sample have to be aggregated into two groups, a process that can lead to discordant conclusions, depending on how the groups are aggregated \[[@CR16]••, [@CR20], [@CR22]\]. Analysis based on the AUROC can also be biased by the way in which the proportion of each stage of fibrosis in the sample fits the distribution in the reference population to which the indices are applied. As a result, the comparison of different AUROCs based on samples with different stage distributions may be flawed (spectrum effect) \[[@CR16]••, [@CR20], [@CR22], [@CR23]••\]. The spectrum effect reflects the inherent variation in test performance among population subgroups. Subgroup variation is not a bias, but is clinically relevant information to be identified and reported with appropriate analyses. If a spectrum effect is possible, heterogeneity should be assessed by subgroup analyses of test performance.

To overcome these methodologic issues, two methods were recently proposed and validated for fibrosis staging and activity grading in patients with CHC. We proposed a standardization of the AUROC for the distribution of fibrosis stages to deal with the spectrum effect \[[@CR20], [@CR23]••\]. Lambert et al. \[[@CR16]••\] proposed using the Obuchowski measure to overcome both spectrum effect and ordinal scale. This measure can be used in situations in which the gold standard is not binary. Furthermore, the Obuchowski measure allows comparison of two biomarkers with a single test, avoiding appropriate correction for the type 1 error when comparing two biomarkers for different stages or grades \[[@CR16]••, [@CR22]\].

### Obuchowski Measure {#Sec12}

The Obuchowski measure is a multinomial version of the AUROC. With *N* (=5) categories of the gold standard outcome (histologic activity grade) and AUROCst (the estimate of the AUROC of diagnostic tests for differentiating between categories *s* and *t*), the Obuchowski measure is a weighted average of the $\documentclass[12pt]{minimal}
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Each pairwise comparison was weighted to take into account the distance between activity grades (ie, the number of units on the ordinal scale). A penalty function proportional to the difference in METAVIR units between grades was defined: the penalty function was 0.25 when the difference between stages was 1; 0.50 when the difference between stages was 2; 0.75 when the difference was 3; and 1 when the difference was 4. The Obuchowski measure can be interpreted as the probability that the noninvasive index will correctly rank two randomly chosen patient samples from different fibrosis stages according to the weighting scheme, with a penalty for misclassifying patients. Note that the overall Obuchowski measure is not equivalent to a usual AUROC curve, because the measurements are weighted according to the distance between stages. The FibroTest cutoffs were those recommended by the manufacturer since the first validation using biopsy: 0.27 for F1, 0.48 for F2, and 0.58 for F3 and 0.74 for F4 \[[@CR20]\]. For ALT, the a priori simple cutoffs chosen were 25, 50, 75, and 100 IU/L, because we previously demonstrated that the expression of ALT activity using the upper limit of normal was hazardous \[[@CR26]\].

### Main Endpoint {#Sec13}

The main endpoint was the accuracy estimated with Obuchowski measure. The FibroTest accuracy was compared with ALT, a standard marker of liver disease severity in CHB \[[@CR15]••\].

### Sensitivity Analyses {#Sec14}

Sensitivity analyses were performed in the integrated database by comparing FibroTest performances according to the variability factors: gender, biopsy length \[[@CR27]\], ethnicity, hepatitis B early antigen (HBeAg) status, HBV genotype, viral load, and ALT value. In one study, patients were included twice, because they had FibroTest and biopsy once before and once after the treatment; a sensitivity analysis was performed comparing patients before and after treatment. When a difference was suspected (*P* \< 0.10) between nonstandardized AUROCs for advanced fibrosis, Obuchowski measures were assessed.

Each estimate was given with its 95% confidence interval (95% CI). Analyses were performed on NCSS software (Kaysville, Utah, USA) \[[@CR28]\] and on R software \[[@CR29]\].

Results {#Sec15}
=======

Databases {#Sec16}
---------

The search retrieved 42 references: 22 for FibroTest, 17 for LSM, two for Hepascore, and one for ELF score. From the 41, 17 were pre-included as original diagnostic studies including only CHB, and 15 studies fully satisfied the inclusion criteria (Table [1](#Tab1){ref-type="table"}). Only one prognostic study was identified \[[@CR18]••\]. Table 1Characteristics of the FibroTest diagnostic studies (*n* = 8) for the staging of hepatic fibrosis in patients with chronic hepatitis BStudyNumber of patientsMethodology cause if mixed (n)Age (y)Stage/prevalenceAUROC SEF0 (%)F1 (%)F2 (%)F3 (%)F4 (%)DANASize (mm)IndependentBiopsy FT/median daysFibroTestMyers et al. \[[@CR10]\]209Prospective (42), Retrospective (167)39F2F3F4 0.290.7876 (36)72 (34)32 (15)10 (5)19 (9)2.3118No10.04F4 0.090.870.04Poynard et al. \[[@CR11]\]214Prospective40F2F3F4 0.670.7714 (8)53 (25)119 (24)55 (26)40 (19)2.17?Mixed1500.03F4 0.19Sebastiani et al. \[[@CR12]\]110Prospective43F2F3F4 0.690.85(14)(18)(36)(12)(20)2.1917Yes00.04F4Zhao et al. \[[@CR13]\]123Prospective?F2F3F40.8125 (20)27 (22)31 (25)29 (24)11 (9)2.20?Yes?0.04F40.720.07Poynard et al. \[[@CR14]•\]924Retrospective39F2F3F4 0.330.7621 (2)596 (65)160 (17)69 (7)78 (8)1.7713Mixed900.02F4 0.080.830.02Gui et al. \[[@CR30]\]100Prospective?F2F3F40.84???????Yes00.05F40.860.07Bottero et al. \[[@CR31]\]108Prospective, HIV coinfected42F2F3F4 0.570.7711 (9)36 (33)28 (26)17 (16)16 (15)2.0417Yes300.04F4 0.150.870.09Bonnard et al. \[[@CR32]\]54Prospective35F2F3F4 0.700.795 (8)13 (22)19 (32)8 (14)14 (24)2.2621Mixed1200.06F4 0.240.850.05FibroTest integrated database^a^1303Retrospective and prospective (1303)39F2F3F4 0.380.76108 (8)707 (54)227 (17)133 (10)128 (10)1.9415^b^Mixed900.03F4 0.100.790.02HepascoreBottero et al. \[[@CR31]\]108Prospective, HIV coinfected42F2F3F4 0.570.7411 (10)36 (33)28 (26)17 (16)16 (15)2.0417Yes300.04F4 0.150.910.09Zhou et al. \[[@CR38]\]146Prospective33F2F3F40.7715632627152.26\>15Yes70.470.06(10)(43)(18)(18)(10)F4 0.100.780.05ElastographyFraquelli et al. \[[@CR37]\]104Prospective45F2F3F4 0.52???21 (20)17 (16)16 (16)?30YesSame sessionF4 0.16?Miailhes et al. \[[@CR36]\]59Prospective43F2F3F40.854 (7)19 (32)16 (27)8 (14)12 (20)2.0616Yes30.05F40.960.02Marcellin et al. \[[@CR33]\]173Prospective40F2F3F4 0.500.8216 (9)70 (41)44 (25)29 (17)14 (8)1.8416Yes20.04F4 0.080.930.08Wang et al. \[[@CR35]\]88Prospective?F2F3F4 ?0.86??????15Yes?0.05F4 ?0.890.04Sporea et al. \[[@CR34]\]140Retrospective39F2F3F4 0.770.661 (0.7)32 (23)67 (48)33 (24)7 (5)1.47\>20YesSame session0.05F4 0.050.970.08Bonnard et al. \[[@CR32]\]54Prospective35F2F3F4 0.700.875 (8)13 (22)19 (32)8 (14)14 (24)2.2621Mixed1200.04F4 0.240.880.03^a^54 patients have been excluded from the original studies as acute hepatitis suspected (ALT \>622 IU/L; *n* = 36) or coinfected with hepatitis delta virus (*n* = 18)^b^Available in 1,090 patients*?* Not available in the article*ALT* alanine aminotransferase, *AUROC* area under the receiver operating curve, *DANA* Difference between Advanced and Non Advanced mean fibrosis stages

For FibroTest, eight studies were pre-included, and all were included for not-standardized meta-analysis for advanced fibrosis. Since the previous meta-analysis, three new studies were included \[[@CR30]--[@CR32]\]. One study was not included in the standardized meta-analysis because it did not provide prevalence of each fibrosis stage \[[@CR30]\]. One study did not provide data for cirrhosis \[[@CR11]\].

For LSM measured by FibroScan, six studies were pre-included and five were included for meta-analysis \[[@CR33]--[@CR37]\]. One was excluded because it did not provide AUROC \[[@CR37]\], and one was not included in the standardized meta-analysis because it did not provide prevalence of each fibrosis stage \[[@CR35]\].

For Hepascore, two studies were pre-included and both included in the meta-analysis (Table [1](#Tab1){ref-type="table"}) \[[@CR31], [@CR38]\].

For the integrated database, we excluded six patients with acute hepatitis suspected by security algorithms \[[@CR8]\], explaining differences in the total number of subjects between integrated database (*n* = 1,303) and the published studies (*n* = 1,309) \[[@CR10], [@CR11]\].

Comparison Between Biomarker Performances According to Published Studies {#Sec17}
------------------------------------------------------------------------

### Diagnosis of Advanced Fibrosis {#Sec18}

Not-standardized AUROCs were all significantly higher than the random 0.50 value (*P* \< 0.001). Mean AUROC was 0.80 (95% CI, 0.77--0.82). There was no significant difference among performance of the three biomarkers: FibroTest AUROC = 0.79 (0.76--0.82), HepaScore AUROC = 0.75 (0.66--0.84), and LSM AUROC = 0.84 (0.78--0.89). There was no significant heterogeneity between studies (Cochran heterogeneity test = 9.5, *P* = 0.80).

Standardized AUROCs, taking into account the spectrum of fibrosis stages, were all significantly higher than the random 0.50 value (*P* \< 0.001) (Fig. [1](#Fig1){ref-type="fig"}). Mean StAUROC was 0.84 (95% CI, 0.80--0.87). There was no significant difference among the performance of the three biomarkers: FibroTest StAUROC = 0.84 (0.79--0.86), HepaScore StAUROC = 0.80 (0.71--0.89), and LSM StAUROC = 0.89 (0.83--0.96). There was no significant heterogeneity between studies (Cochran heterogeneity test = 6.3, *P* = 0.90). Fig. 1Meta-analysis of the area under the receiver operating curve (*AUROC*) observed in published studies of Fibrotest, HepaScore, and liver stiffness measurement (*LSM*) for the diagnosis of advanced fibrosis in patients with chronic hepatitis B. Standardized AUROCs (StAUROCs), taking into account the spectrum of fibrosis stages, were all significantly higher than the random 0.50 value (*P* \< 0.001). Mean StAUROC was 0.84 (95% CI, 0.80--0.87). There was no significant difference among performance of the three biomarkers: FibroTest StAUROC = 0.84 (0.79--0.86), HepaScore StAUROC = 0.80 (0.71--0.89), and LSM StAUROC = 0.89 (0.83--0.96). There was no significant heterogeneity between studies (Cochran heterogeneity test = 6.3, *P* = 0.90)

### Diagnosis of Cirrhosis {#Sec19}

Not-standardized AUROCs were all significantly higher than the random 0.50 value (*P* \< 0.001). Mean AUROC was 0.87 (95% CI, 0.82--0.91). There was no significant difference among the performance of the three biomarkers: FibroTest AUROC = 0.83 (0.78--0.87), HepaScore AUROC = 0.86 (0.74--0.98), and LSM AUROC = 0.93 (0.87--0.99). There was no significant heterogeneity between studies (Cochran heterogeneity test = 15.1, *P* = 0.13).

Standardized AUROCs, taking into account the spectrum of fibrosis stages, were all significantly higher than the random 0.50 value (*P* \< 0.001). Mean StAUROC was 0.89 (95% CI, 0.85--0.92). There was no significant difference among the performance of the three biomarkers: FibroTest StAUROC = 0.85 (0.80--0.90), HepaScore StAUROC = 0.88 (0.76--1.00), and LSM StAUROC = 0.96 (0.90--1.00). There was no significant heterogeneity between studies (Cochran heterogeneity test = 16.6, *P* = 0.09).

### Sensitivity Analysis {#Sec20}

There was no difference between the performances of FibroTest according to the independence of authors. The not-standardized AUROC for advanced fibrosis was 0.83 (0.78--0.87) for the four independent publications and 0.77 (0.73--0.81) for the four dependent publications. The other performances were also not significant (data not shown).

FibroTest's Performance According to Individual Data Meta-Analysis (Table [2](#Tab2){ref-type="table"}) {#Sec21}
-------------------------------------------------------------------------------------------------------

### Performance Between All Fibrosis Stages {#Sec22}

The overall mean (95% CI) accuracy of FibroTest (Obuchowski measure) was 0.844 (0.832--0.856), greater than that of ALT, which was 0.803 (0.791--0.815), *P* \< 0.0001. FibroTest's performances were particularly greater than those of ALT for the diagnosis between F0 and F1 (0.61 \[0.56--0.66\] vs 0.52 \[0.46--0.58\]) and between F3 and F4 (0.58 \[0.52--0.64\] vs 0.50 \[0.44--0.56\]). Table 2Sensitivity analyses of FibroTest diagnostic values according to patient characteristicsAdvanced fibrosisPairwise comparisons between all stages, Obuchowski measureCharacteristic (no. of patients)Not standardized AUROCSignificance (*P*)AUROC (95% CI)All (1303)0.76 (0.73--0.79)0.844 (0.832--0.856)Gender\>0.10Male (941)0.75 (0.72--0.78)Female (362)0.76 (0.70--0.81)Length of biopsy\>0.10\<25 mm (942)0.76 (0.71--0.85)≥25 mm (148)0.79 (0.71--0.85)Not available (213)0.76 (0.69--0.82)Ethnicity^a^0.06*P* \> 0.10Asian (546)0.72 (0.67--0.76)0.836 (0.814--0.848)Caucasian (601)0.78 (0.74--0.82)0.853 (0.839--0.867)Sub-Saharan (156)^b^0.80 (0.72--0.86)HBeAg^c,d^0.046*P* \> 0.10Absent (548)0.73 (0.68--0.77)^e^0.854 (0.838--0.870)Present (753)0.78 (0.75--0.82)0.831 (0.814--0.848)After treatment\>0.10No (723)0.75 (0.71--0.78)Yes (392)0.78 (0.72--0.82)Not available (188)0.78 (0.70--0.85)HBV genotype\>0.10Genotype A (61)0.77 (0.57--0.88)Genotype non-A (137)0.77 (0.73--0.79)Not available (1105)0.76 (0.73--0.79)Viral load (IU/mL)\>0.10\<3 Log (276)0.79 (0.73--0.84)3--5 Log (115)0.82 (0.72--0.88)5--7 Log (330)0.72 (0.66--0.77)\>7 Log (464)0.77 (0.72--0.81)Not available (118)0.76 (0.65--0.83)ALT \<50 IU/L\>0.10No (825)0.75 (0.72--0.79)Yes (478)0.76 (0.70--0.80)ALT \<25 IU/L\>0.10No (1151)0.76 (0.73--0.79)Yes (152)0.72 (0.57--0.82)^a^In Asian patients (*n* = 546) the overall mean (95% CI) accuracy of FibroTest (standardized using Obuchowski measure) was 0.827 (0.807--0.846), no different than that of non-Asian (*n* = 757), 0.853 (0.839--0.867), (NS)^b^African American also included^c^In 2 patients, status was unknown^d^In patients with presence of HBeAg (*n* = 753) the overall mean (95% CI) accuracy of FibroTest (standardized using Obuchowski measure) was 0.831 (0.814--0.848), no different than that of patients without HBeAg (*n* = 548), 0.854 (0.838--0.870), (NS)^e^*P* = 0.046 vs "present"*ALT* alanine aminotransferase, *AUROC* area under the receiver operating curve, *HBeAg* hepatitis B early antigen, *HBV* hepatitis B virus

### Sensitivity Analyses {#Sec23}

Using not-standardized AUROC, FibroTest had a lower performance in patients without HBeAg (0.73 \[0.68--0.77\]) versus patients with HBeAg (0.78 \[0.75--0.82\]; *P* = 0.046), and in Asian patients (0.72 \[0.67--0.76\]) versus non-Asian patients (0.78 \[0.74--0.82\]). These differences were no more significant using Obuchowski measures: 0.831 (0.814--0.848) versus 0.854 (0.838--0.870; *P* \> 0.10) for HBeAg status, and 0.836 (0.814--0.848) versus 0.853 (0.839--0.867; *P* \> 0.10) for ethnicity (Table [2](#Tab2){ref-type="table"}). All the other characteristics were not associated with significant variability in the performances of FibroTest.

Prognostic Value of Fibrosis Biomarkers in CHB {#Sec24}
----------------------------------------------

Only one published study was identified concerning FibroTest \[[@CR18]••\]. The first aim of this study was to compare the 4-year prognostic value of FibroTest and ActiTest to that of viral load and to that of biopsy (in a subpopulation with simultaneous biopsy). The second aim of the study was to compare the 4-year prognostic value of combining FibroTest, ActiTest, and viral load for a better definition of the inactive HBV carrier status.

The main endpoint was the absence of liver-related complications. Liver-related complications were defined as death, liver transplantation, or one of the following: decompensation (ascites, hepatic encephalopathy, or jaundice with total bilirubin \>51 μmol/L), variceal bleeding, or hepatocellular carcinoma. The adjustment factors were age, sex, HBeAg, ethnic origin, alcohol consumption, HIV-Delta-hepatitis C virus coinfection, and treatment.

The study included 1,074 patients with baseline FibroTest, ActiTest, and viral load (41 years old, 69% male, 47% African, 27% Asian, 20% Caucasian, 15.5% coinfected, mean follow-up 7.7 years \[2.5 years prospective and 5.2 years retrospective\]). Manufacturers' definitions were used for normal FibroTest (≤0.27), and normal ActiTest (≤0.29). The prevalences of a three-class viral load in international units per milliliter (low = \<log 3, intermediate = log 3--log 5, high = \>log 5) were 55%, 28%, and 17%, respectively. The accuracy (AUROC \[95% CI\]) of FibroTest in 97 patients with simultaneous liver biopsies for the diagnosis of advanced fibrosis was similar to previous validations (AUROC = 0.83 \[0.71--0.91\]), and higher than ALT (0.60 \[0.47--0.71\]) and viral load (0.53 \[0.39--0.63\]) (all *P* \< 0.0001), and not different from liver biopsy (*P* = ns).

At 4-years' follow-up, 50 complications occurred (survival without complications was 93.4%) and 36 deaths (survival was 95.0%), including 27 related to HBV (survival was 96.1%). The prognostic value of FibroTest was higher than that of viral load or ALT when compared using AUROC curves (all *P* \< 0.0001), survival curves, and multivariate Cox model. Among the 336 patients (without coinfection with hepatitis C virus, Delta, or HIV) with the classic definition of inactive carrier, 74 (22%) had advanced fibrosis presumed with FibroTest, and three died or had complications at 4 years' follow-up. A new definition of inactive carriers was proposed, with an algorithm combining "zero" scores for FibroTest and ActiTest (F0 and A0) and viral load classes. This new algorithm provided a 100% negative predictive value for the prediction of liver-related complications or death at 4 years.

Discussion {#Sec25}
==========

This overview largely confirmed in patients with CHB the diagnostic performance of FibroTest and LSM by Fibroscan, which was already extensively validated in patients with CHC \[[@CR1]--[@CR10]\]. These performances were highly significant both for the diagnosis of advanced fibrosis and for the diagnosis of cirrhosis. The other fibrosis biomarkers have been less studied, preventing any conclusions. Only two studies have been identified for Hepascore, but the performances were also similar to those in patients with CHC.

Strength of the Study {#Sec26}
---------------------

The methodology of the present overview permitted taking into account the spectrum effect in the assessment of performances and identification of factors associated with variability. The same biomarker can have an AUROC of 0.87 for discriminating stages from F0 to F4 and an AUROC of 0.51 for discriminating between stages F1 and F2 (Table [1](#Tab1){ref-type="table"}). As in patients with CHC, there was a clear risk of misleading conclusions if biomarkers were indirectly compared without standardizations on fibrosis spectrum. The Obuchowski method permitted validation of the higher performance of FibroTest versus ALT for the diagnosis of fibrosis stages.

The methods permitted accounting for the spectrum variability between Asian and non-Asian patients as well as between HBeAg-positive and HBeAg-negative patients. There was also no impact of the authorship with same FibroTest performances among independent and not-independent publications.

Limits of the Study {#Sec27}
-------------------

### Reliability of Biomarkers {#Sec28}

The present overview was not designed to assess the failure rate and the reliability rate of the biomarkers, which are a main concern in the clinical performance. From recent large studies, LSM has a weakness in comparison to serum biomarkers, with a 3.1% failure rate and 15.8% unreliable results \[[@CR39]••,[@CR40]•\], compared to 0% failure for FibroTest and less than 5% unreliable results \[[@CR8]\]. The most frequent causes of unreliable results for Fibroscan are necro-inflammatory activity flares and metabolic factors, and for FibroTest, hemolysis and acute inflammation \[[@CR8], [@CR39]••, [@CR40]•\].

### Individual Data {#Sec29}

Another weakness was to have only individual data for FibroTest and not for LSM. Only the analysis of large databases can identify sources of variability in the diagnostic performances of biomarkers \[[@CR20], [@CR41]••\], including the variability of biopsy, the imperfect gold standard \[[@CR27]\]. The mean length of biopsy was small in the present studies (usually \<20 mm), including in the individual database (15 mm), and it was reassuring that the performances of Fibrotest were stable in the sensitivity analysis. Furthermore, standardization of AUROCs requires individual data, both for using DANA correction and Obuchowski measures \[[@CR16]••, [@CR22], [@CR23]••\].

### Absence of a True Gold Standard {#Sec30}

Because of the limitations of biopsy, even with 25-mm length, a need exists to improve the assessment of liver biomarker performances using methods without gold standards \[[@CR41]••, [@CR42], [@CR43]•\]. No latent class analyses have been performed in CHB, and only one study has demonstrated the prognostic value of FibroTest in CHB \[[@CR18]••\], confirming those already observed in patients with CHC \[[@CR43]•\] and alcoholic liver disease \[[@CR44]•\].

Conclusions {#Sec31}
===========

This overview suggests that FibroTest and Fibroscan could be used as an alternative to liver biopsy in patients with CHB. However, for Fibroscan, a large analysis of individual data using Obuchowski measures seems necessary to assess the impact of necroinflammatory activity grades and steatosis, particularly for the diagnosis of advanced fibrosis. However, neither biomarkers nor biopsy are sufficient, alone, to make a definitive decision in a given patient, and all the clinical and biological data must be taken into account.

This study reinforced our previous conclusion that, based on current evidence, a wise recommendation in patients with CHB would be a moratorium on liver biopsy as a first-line procedure, while awaiting studies demonstrating its cost utility versus that of biomarkers \[[@CR45]\]. Biopsy as a second-line estimate of liver injury should still be indicated for intricate disease or clinicobiological discordances.
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